These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26048902)

  • 1. Decision-theoretic designs for small trials and pilot studies: A review.
    Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
    Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approximately optimal designs for phase II clinical studies.
    Stallard N
    J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision-theoretic designs for phase II clinical trials allowing for competing studies.
    Stallard N
    Biometrics; 2003 Jun; 59(2):402-9. PubMed ID: 12926725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical challenges in assessing potential efficacy of complex interventions in pilot or feasibility studies.
    Wilson DT; Walwyn RE; Brown J; Farrin AJ; Brown SR
    Stat Methods Med Res; 2016 Jun; 25(3):997-1009. PubMed ID: 26071430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.
    Zhao L; Taylor JM; Schuetze SM
    Stat Med; 2012 Jul; 31(17):1804-20. PubMed ID: 22359354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal sample sizes for phase II clinical trials and pilot studies.
    Stallard N
    Stat Med; 2012 May; 31(11-12):1031-42. PubMed ID: 22052407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample sizes for phase II clinical trials derived from Bayesian decision theory.
    Brunier HC; Whitehead J
    Stat Med; 1994 Dec 15-30; 13(23-24):2493-502. PubMed ID: 7701149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision theoretic designs for phase II clinical trials with multiple outcomes.
    Stallard N; Thall PF; Whitehead J
    Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bayesian approach to the design of phase II clinical trials.
    Sylvester RJ
    Biometrics; 1988 Sep; 44(3):823-36. PubMed ID: 3203131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
    Chen C; Beckman RA
    J Biopharm Stat; 2009; 19(3):424-36. PubMed ID: 19384686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian two-stage designs for phase II clinical trials.
    Tan SB; Machin D
    Stat Med; 2006 Oct; 25(19):3407-8. PubMed ID: 16847890
    [No Abstract]   [Full Text] [Related]  

  • 20. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.